![Errol de Souza](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Errol de Souza
Président chez
CYCLERION THERAPEUTICS, INC.
Fortune : 63 M $ au 30/06/2026
Profil
Errol B. de Souza was the founder of Neurocrine Biosciences, Inc., founded in 1992, where the title held was Director, Executive VP-Research & Development from 1992 to 1998.
Current jobs include Chairman at Cyclerion Therapeutics, Inc. since 2021; Director at Kures, Inc.; Independent Director at Alector, Inc. starting in 2024; and Director at Bionaut Labs, Inc. Former jobs include President, Chief Executive Officer & Director at Lundbeck Research USA, Inc. from 2002 to 2003; President, Chief Executive Officer & Director at Archemix Corp.
from 2003 to 2009; President, Chief Executive Officer & Director at Biodel, Inc. from 2011 to 2016; President, Chief Executive Officer & Director at Neuropore Therapies, Inc. from 2017 to 2019; President & Chief Executive Officer at Albireo Pharma, Inc.; Chairman-Technology Committee at Merial, Inc.; Executive Chairman at nLife Therapeutics SL; Director at IDEXX Laboratories, Inc. from 2003 to 2009; Director at Palatin Technologies, Inc. from 2003 to 2010; Non-Executive Director at Bionomics Ltd. from 2008 to 2023; Independent Director at Targacept, Inc. from 2011 to 2015; Independent Director at Catalyst Biosciences, Inc. from 2015 to 2022; Independent Director at Royalty Pharma Plc from 2020 to 2026; Senior VP, Head-Research & Development at Aventis Pharmaceuticals, Inc. from 1998 to 2002; Head-CNS Diseases Research at DuPont Merck Pharmaceutical Co. from 1990 to 1992; and Senior VP, Head-Research & Development at Hoechst Marion Roussel, Inc. from 1998 to 2002.
Education includes undergraduate and doctorate degrees from the University of Toronto.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
RPI US Partners 2019 LP
 RPI US Partners 2019 LP Financial ConglomeratesFinance Functions as an investment fund 0,25 % | 16/06/2020 | 539 150 ( 0,25 % ) | 30 M $ | 30/06/2026 |
| 06/04/2026 | 500 140 ( 0,21 % ) | 28 M $ | 30/06/2026 | |
| 06/04/2026 | 81 352 ( 0,02 % ) | 5 M $ | 30/06/2026 | |
ALECTOR, INC. 0,09 % | 17/06/2026 | 98 650 ( 0,09 % ) | 198 287 $ | 30/06/2026 |
| 30/03/2026 | 50 000 ( 1,15 % ) | 169 500 $ | 30/06/2026 |
Postes actifs de Errol de Souza
| Sociétés | Poste | Début |
|---|---|---|
| CYCLERION THERAPEUTICS, INC. | Président | - |
| ALECTOR, INC. | Directeur/Membre du Conseil | 19/03/2024 |
Kures, Inc.
 Kures, Inc. BiotechnologyHealth Technology Develops therapeutics for mood disorders | Directeur/Membre du Conseil | - |
Bionaut Labs, Inc.
 Bionaut Labs, Inc. Miscellaneous Commercial ServicesCommercial Services Provides imagine services for precision medicines and drugs | Directeur/Membre du Conseil | - |
Anciens postes connus de Errol de Souza
| Sociétés | Poste | Fin |
|---|---|---|
| ROYALTY PHARMA PLC | Directeur/Membre du Conseil | 09/06/2026 |
Bionomics Ltd.
 Bionomics Ltd. Pharmaceuticals: GenericHealth Technology Develops drug for treatment of central nervous system disorders | Président | 01/07/2023 |
| CATALYST BIOSCIENCES | Directeur/Membre du Conseil | 26/12/2022 |
Neuropore Therapies, Inc.
 Neuropore Therapies, Inc. BiotechnologyHealth Technology Develops small molecule therapeutics for the treatment parkinson’s disease | Directeur Général | 01/12/2019 |
Biodel, Inc.
 Biodel, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Directeur Général | 26/01/2016 |
Formation de Errol de Souza
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
66
Relations au 1er degré
22
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 22 |
|---|---|
IDEXX Laboratories, Inc.
 IDEXX Laboratories, Inc. Medical SpecialtiesHealth Technology Develops animal diagnostic, software and imaging & water treatment systems | Health Technology |
Lundbeck Research USA, Inc.
 Lundbeck Research USA, Inc. Pharmaceuticals: MajorHealth Technology Provides pharmaceutical products | Health Technology |
Neurocrine Biosciences, Inc.
 Neurocrine Biosciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes treatments for neurological, neuroendocrine and neuropsychiatric disorders | Health Technology |
Palatin Technologies, Inc.
 Palatin Technologies, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops medicines based on molecules for the modulation of melanocortin receptor system | Health Technology |
Archemix Corp.
 Archemix Corp. Miscellaneous Commercial ServicesCommercial Services Provides molecular biology research to develop new drugs | Commercial Services |
Biodel, Inc.
Biodel, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Aventis Pharmaceuticals, Inc.
 Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Health Technology |
Bionomics Ltd.
Bionomics Ltd. Pharmaceuticals: GenericHealth Technology Develops drug for treatment of central nervous system disorders | Health Technology |
DuPont Merck Pharmaceutical Co.
 DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Makes pharmaceuticals and drugs | Health Technology |
Targacept, Inc.
 Targacept, Inc. Pharmaceuticals: OtherHealth Technology Discovers and develops nicotinic acetylcholine receptor based therapies | Health Technology |
University of Toronto
 University of Toronto Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Merial, Inc.
 Merial, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products and vaccines for pets, production animals, horses, and wildlife | Health Technology |
Hoechst Marion Roussel, Inc.
 Hoechst Marion Roussel, Inc. Pharmaceuticals: GenericHealth Technology Develops, manufactures and sells generic pharmaceutical products | Health Technology |
nLife Therapeutics SL
 nLife Therapeutics SL Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical preparations | Health Technology |
Alector, Inc.
 Alector, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops therapeutics for Alzheimer’s disease and other neurodegenerative disorders | Health Technology |
Neuropore Therapies, Inc.
Neuropore Therapies, Inc. BiotechnologyHealth Technology Develops small molecule therapeutics for the treatment parkinson’s disease | Health Technology |
Catalyst Biosciences, Inc.
 Catalyst Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company | Health Technology |
Albireo Pharma, Inc.
 Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets novel bile acid modulators for liver and gastrointestinal diseases and disorders | Health Technology |
Cyclerion Therapeutics, Inc.
 Cyclerion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes pharmaceutical products for serious and orphan diseases | Health Technology |
Bionaut Labs, Inc.
Bionaut Labs, Inc. Miscellaneous Commercial ServicesCommercial Services Provides imagine services for precision medicines and drugs | Commercial Services |
Kures, Inc.
Kures, Inc. BiotechnologyHealth Technology Develops therapeutics for mood disorders | Health Technology |
Royalty Pharma Plc
 Royalty Pharma Plc Pharmaceuticals: MajorHealth Technology Buys and operates a portfolio of biopharmaceutical royalties | Health Technology |
